Cynosure Continues to Expand the Smartlipo(TM) LaserBodySculpting Product Family
October 29 2007 - 8:30AM
PR Newswire (US)
New 18-Watt System Launched at Plastic Surgery 2007 Meeting
WESTFORD, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Cynosure, Inc.
(NASDAQ:CYNO), a leading developer and manufacturer of a broad
array of light-based aesthetic treatment systems, today announced
the addition of an 18-watt workstation to its family of Smartlipo
LaserBodySculpting(SM) products. This higher-power workstation will
allow physicians to continue to reduce patient treatment times for
laser-assisted liposuction. Cynosure is introducing the 18-watt
Smartlipo at the American Society of Plastic Surgeons (ASPS)
meeting, Plastic Surgery 2007, which is continuing through October
31 at the Baltimore Convention Center. In addition to its new
18-watt system, Cynosure (booth #906) offers Smartlipo in
upgradeable configurations of 6-watt and 10-watt workstations, each
designed to address the specific needs of an aesthetic practice.
All systems in the field can be upgraded to the new 18-watt system.
"The 18-watt Smartlipo workstation provides practitioners a highly
efficient approach for performing laser-assisted liposuction, with
the same level of safety and efficacy as earlier versions," said
Bruce Katz, M.D., founder of New York's Juva Skin & Laser
Center. "For example, an area of localized fat within an abdomen
can be treated in about 12 minutes with the 18-watt Smartlipo,
compared with about 35 minutes with the 6-watt workstation."
Launched in January, Cynosure's minimally invasive Smartlipo
workstation is an innovative system designed as an alternative to
traditional liposuction in patients with smaller areas of localized
fat. The system's proprietary pulsing format delivers laser energy
that liquefies the fat, which is then removed through a cannula.
The Smartlipo's laser energy also coagulates the tissue, thereby
sculpting body contours and tightening the skin. The procedure
generally causes less bleeding, swelling and bruising than
traditional liposuction, resulting in fewer complications and
faster recovery. Cynosure received U.S. Food and Drug
Administration clearance to market Smartlipo in the fourth quarter
of 2006. "The addition of the more powerful 18-watt system to our
Smartlipo product family is designed to benefit physicians, such as
plastic surgeons and dermatologists, who are experienced in body
sculpting," said Cynosure President and Chief Executive Officer
Michael Davin. "The minimally invasive nature of the Smartlipo
makes it an increasingly attractive option for active patients who
want to remove localized areas of fat through a procedure that
keeps lifestyle disruption to a minimum. As a result, we believe
Smartlipo is enjoying a high level of satisfaction from physicians
and patients." In conjunction with its launch of the new 18-watt
Smartlipo system, Cynosure is hosting The Laser Assisted
Liposuction Symposium during Plastic Surgery 2007. Moderated by Dr.
Barry DiBernardo, medical director of New Jersey Plastic Surgery,
the symposium will feature a panel discussion on areas including
the history and science of laser lipolysis, clinical indications
and patient outcomes. About Cynosure, Inc. Cynosure, Inc. develops
and markets aesthetic treatment systems that are used by physicians
and other practitioners to perform non-invasive and minimally
invasive procedures to remove hair, treat vascular lesions,
rejuvenate skin through the treatment of shallow vascular and
pigmented lesions, laser lipolysis and temporarily reduce the
appearance of cellulite. Cynosure's products include a broad range
of laser and other light-based energy sources, including
Alexandrite, pulsed dye, Nd: YAG and diode lasers, as well as
intense pulsed light. Cynosure was founded in 1991. For corporate
or product information, contact Cynosure at 800-886-2966, or visit
http://www.cynosure.com/. Safe Harbor Any statements in this press
release about future expectations, plans and prospects for
Cynosure's 18-watt Smartlipo LaserBodySculpting(SM) system
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
contain the words "believes," "anticipates," "plans," "expects,"
"will" and similar expressions. Actual results may differ
materially from those indicated by such forward- looking statements
as a result of various important factors, including Cynosure's
history of operating losses, its reliance on sole source suppliers,
the inability to accurately predict the success of the 18-watt
Smartlipo workstation, changes in consumer preferences, competition
in the aesthetic laser industry as well economic, market,
technological and other factors discussed in Cynosure's most recent
Annual Report on Form 10-K, which is filed with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent Cynosure's views as of the
date of this press release. Cynosure anticipates that subsequent
events and developments will cause its views to change. However,
while Cynosure may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing Cynosure's views as of any date
subsequent to the date of this press release. DATASOURCE: Cynosure,
Inc. CONTACT: Scott Solomon, Vice President of Sharon Merrill
Associates, Inc., +1-617-542-5300, , for Cynosure, Inc. Web site:
http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024